HURA TuHURA Biosciences Inc.

Price (delayed)

$2.05

Market cap

$130.64M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$0.54

Enterprise value

$138.82M

Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 3

TuHURA Biosciences, Inc. is a Phase 3 immuno-oncology company developing novel technologies to overcome primary and acquired resistance to cancer immunotherapy, two of the most common reasons cancer immunotherapies fail ...

Highlights
TuHURA Biosciences's EPS has increased by 27% YoY and by 11% from the previous quarter
The quick ratio has plunged by 89% from the previous quarter and by 80% YoY
TuHURA Biosciences's equity has decreased by 20% from the previous quarter and by 4.9% YoY

Key stats

What are the main financial stats of HURA

HURA stock price

How has the TuHURA Biosciences stock price performed over time
Intraday
-3.76%
1 week
0.99%
1 month
2.5%
1 year
-18%
YTD
170.91%
QTD
-12.39%

Financial performance

How have TuHURA Biosciences's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$31.2M
Net income
-$30.62M
Gross margin
N/A
Net margin
N/A
TuHURA Biosciences's operating income has decreased by 19% YoY but it has increased by 3.4% QoQ
The net income fell by 10% YoY

Price vs fundamentals

How does HURA's price correlate with its fundamentals

Growth

What is TuHURA Biosciences's growth rate over time

Valuation

What is TuHURA Biosciences stock price valuation
P/E
N/A
P/B
7.06
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
TuHURA Biosciences's EPS has increased by 27% YoY and by 11% from the previous quarter
The P/B is 56% higher than the 5-year quarterly average of 4.7 and 31% higher than the last 4 quarters average of 5.6
TuHURA Biosciences's equity has decreased by 20% from the previous quarter and by 4.9% YoY

Efficiency

How efficient is TuHURA Biosciences business performance
The return on invested capital has surged by 91% year-on-year and by 62% since the previous quarter
HURA's return on equity is up by 39% year-on-year
HURA's ROA is up by 32% YoY

Dividends

What is HURA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for HURA.

Financial health

How did TuHURA Biosciences financials performed over time
The total assets is 140% more than the total liabilities
TuHURA Biosciences's total liabilities has soared by 103% from the previous quarter but it has decreased by 13% YoY
The quick ratio has plunged by 89% from the previous quarter and by 80% YoY
The debt is 50% smaller than the equity
TuHURA Biosciences's equity has decreased by 20% from the previous quarter and by 4.9% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.